Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1999-04-16
2000-05-23
Davenport, Avis M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 15, 530313, 530328, A61K 3800, C07K 500, C07K 700
Patent
active
060666196
ABSTRACT:
This invention relates to stable non-aqueous protic formulations of peptide compounds. These stable formulations comprise peptide in non-aqueous protic solvent. They may be stored at elevated temperatures for long periods of time and are especially useful in implantable delivery devices for long term delivery of drug.
REFERENCES:
patent: 3914412 (1975-10-01), Gendrich et al.
patent: 4547370 (1985-10-01), Roeske
patent: 4661472 (1987-04-01), Rivier et al.
patent: 4689396 (1987-08-01), Roeske et al.
patent: 4851385 (1989-07-01), Roeske
patent: 5034229 (1991-07-01), Magruder et al.
patent: 5057318 (1991-10-01), Magruder et al.
patent: 5110596 (1992-05-01), Magruder et al.
patent: 5198533 (1993-03-01), Schally et al.
patent: 5480868 (1996-01-01), Kamei et al.
Factrel (gonadorelin HCI for subcutaneous or IV injection), Physician's Desk Ref., 50th Ed., pp. 2877-2878 (1996).
Fu Lu, et al., "Percutaneous Absorption Enhancement of Leuprolide", Pharm. Res., 9/12, pp. 1575-1576 (1992).
Helm, et al., "Stability of Gonadorelin and Triptorelin in Aqueous Solution", Pharm. Res., 7/12, pp. 1253-1256 (1990).
Johnson, et al., "Degradation of the LH-RH Analog Nafarelin Acetate in Aqueous Solution", Intl. J. Pharm., 31, pp. 125-129 (1986).
Lupron (leuprolide acetate for subcutaneous injection), Physician's Desk Ref., 50th Ed., pp. 2555-2556 (1996).
Lupron Depot (leuprolide acetate for depot suspension), Physician's Desk Ref., 50th Ed., pp. 2556-2562 (1996).
Lutrepulse (gonadorelin acetate for IV injection), Physician's Desk Ref., 50th Ed., pp. 980-982 (1996).
Okada, et al., "New Degradation Product of Des-Gly.sup.10 -NH.sub.2 -LH-RH-Ethylamide (Fertirelin) in Aqueous Solution", J. Pharm. Sci., 80/2, pp. 167-170 (1991).
Okada, et al., "Preparation of Three-Month Depot Injectable Microspheres of Leuprorelin Acetate Using Biodegradable Polymers", Pharm. Res., 11/8, pp. 1143-1147 (1994).
Oyler, et al., "Characterization of the Solution Degradation Products of Histrelin, a Gonadotropin Releasing Hormone (LH/RH) Agonist", J. Pharm. Sci., 80/3, pp. 271-275 (1991).
Powell, et al., "Parenteral Peptide Formulations: Chemical and Physical Properties of Native Luteinizing Hormone-Releasing Hormone (LHRH) and Hydrophobic Analogues in Aqueous Solution", Pharm. Res., 8/10, pp. 1258-1263 (1991).
Powell, et al., "Peptide Liquid Crystals: Inverse Correlation of Kinetic Formation and Thermodynamic Stability in Aqueous Solution", Pharm. Res., 11/9, pp. 1352-1354 (1994).
Powers, et al., "Solution Behavior of Leuprolide Acetate, an LHRH Agonist, as Determined by Circular Dichroism Spectroscopy", Int. J. Pharm., 108, pp. 49-55 (1994).
Shi, et al., "Long-Term Stability of Aqueous Solutions of Luteinizing Hormone-Releasing Hormone Assessed by an In-Vitro Bioassay and Liquid Chromatography", J. Pharm. Sci., 73/6, pp. 819-821 (1984).
Toguchi, "Pharmaceutical Manipulation of Leoprorelin Acetate to Improve Clinical Performance", J. Int. Med. Res., 18, pp. 35-41 (1990).
Zoladex (goserelin acetate implant), Physician's Desk Ref., 50th Ed., pp. 2858-2861 (1996).
Eckenhoff James B.
Leonard, Jr. John J.
Prestrelski Steven J.
Stevenson Cynthia L.
Tao Sally A.
ALZA Corporation
Clarke Pauline A.
Davenport Avis M.
Dillahunty Mary Ann
Stone Steven F.
LandOfFree
Non-aqueous protic peptide formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-aqueous protic peptide formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-aqueous protic peptide formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1837151